|
|
|
|
 |
|
||
|
|||
 |
|
||
 |
 |
 |
|
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
Ception Therapeutics to Participate in the Private Company Forum at the 29th Annual Goldman Sachs Global Healthcare Conference
Contact:
Mike Beyer - Sam Brown Inc.
(773) 463-4211 beyer@sambrown.com
MALVERN, PA – June 6, 2008 – Ception Therapeutics Inc. announced today its participation in the Private Company Forum at the 29th Annual Goldman Sachs Global Healthcare Conference on June 9, 2008 from 4:45 p.m.-6:15 p.m. PST in Salons 3 and 4 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. Steve Tullman, co-founder, President and CEO, Tim Henkel, MD, PhD, Executive Vice President of Research and Development, and Doug Gessl, CFO of Ception will be available to discuss the company.
About Ception Therapeutics, Inc.
Ception Therapeutics is an emerging biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. The Company’s pipeline includes a late-stage biologic agent in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. Ception Therapeutics pursues new drug targets in these and other disease areas through a proprietary thermodynamics-based rational drug design platform. For further information, visit www.ceptiontx.com.
